|  | Anticonvulsants | Antidepressants | Antipsychotics | Disulfiram | Baclofen | Acamprosate | Nalmefene | Naltrexone |
---|---|---|---|---|---|---|---|---|---|
Risk of bias | Meta-analyses (AMSTAR) | Low | Low | Very low | Very low | Low | Very low | Moderate | Low |
RCTs | Low | Low | Low | Low | Low | Moderate | Moderate | Low | |
Inconsistency | Meta-analyses | Consistent | Consistent | Consistent | Inconsistent | Inconsistent | Consistent | Consistent (overlap in RCTs) | Very inconsistent |
Heterogeneity of RCTs | High | Low | High | High | Moderate | High | Low | Moderate | |
Indirectness | Applicable | Applicable | Applicable | Applicable | Applicable | Applicable | Applicable | Applicable | |
Imprecision | Confidence interval | Moderate | Wide | Very wide | Wide | Wide | Moderate | Small | Wide |
Sample size | Thousands | Less than 100 | Hundreds | Thousands | Hundreds | Thousands | Hundreds | Thousands | |
Small study effect (number of studies) | Yes (1 topiramate), No (1), NR (3) | Yes (1), No (1), NR (2) | No (1), NR (2) | No (1), Yes (1), NR (3) | No (3), Yes (2), NR (2) | Yes (2), No (3), NR (5) | Yes (1), NR (1) | Yes (2), No (1), NR (5) | |
Other | NA | Effect only in studies with publication bias | Only quetiapine has large effect size | NA | NA | NA | NA | NA | |
Overall | Very low | Very low | Very low | Very low | Very low | Low | Low | Very low |